BioSpace News Archive

Drug Development

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Allyx Therapeutics announced that its lead compound, ALX-001, is ready to proceed to Phase 2 clinical development in Alzheimer’s and Parkinson’s disease.

March 11, 2024
·
4 min read
ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

March 11, 2024
·
3 min read
Drug Development

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)

FSD Pharma Inc. today announces the submission of the Company’s Clinical Trial Application (CTA) for a planned Phase-1b clinical trial to Assess the Safety and Efficacy of unbuzzed in Healthy Volunteers in an Induced State of Alcohol Intoxication (METAL-1 TRIAL).

March 11, 2024
·
7 min read
BioCapital

NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant

The U.S. Patent and Trademark Office has issued a patent, US11920140, for the use of CRISPR technologies to edit organellar genomes to NAPIGEN, Inc., a biotechnology company that specializes in mitochondrial and chloroplast genome engineering.

March 11, 2024
·
2 min read
Deals

Merck Completes Acquisition of Harpoon Therapeutics, Inc.

Merck today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP).

March 11, 2024
·
5 min read
Genetown

bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA.

March 11, 2024
·
12 min read
Policy

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Lexicon Pharmaceuticals, Inc., announced that, following the receipt of recent feedback from FDA, it is preparing to resubmit its New Drug Application for sotagliflozin as an adjunct to insulin therapy for glycemic control in patients with type 1 diabetes and chronic kidney disease.

March 11, 2024
·
3 min read
Biotech Bay

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharmaceuticals Ltd. announced that it has begun to enroll patients in the US under an updated protocol in the ongoing TREK-DX trial, studying eblasakimab in dupilumab-experienced patients with moderate-to-severe atopic dermatitis.

March 11, 2024
·
10 min read
Drug Development

Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen

Following to the previous information on Jan. 30th. in 2024, we are excited to share our latest development status.

March 11, 2024
·
1 min read
BioCapital

REGENXBIO to Participate in Upcoming March 2024 Investor Conferences

REGENXBIO Inc. announced it will participate the following upcoming investor conferences.

March 11, 2024
·
1 min read